Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
| العنوان: | Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor |
|---|---|
| المؤلفون: | Anna Rudakova, Liudmila Buryachkovskaya, Victor L. Serebruany, Nikita Lomakin |
| المصدر: | European Cardiology Review, Vol 14, Iss 3, Pp 175-178 (2019) European Cardiology Review |
| بيانات النشر: | Radcliffe Medical Media, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, Acute coronary syndrome, animal structures, Cost effectiveness, outcomes, antiplatelet therapy, ticagrelor, P2Y12, Internal medicine, Medicine, Diseases of the circulatory (Cardiovascular) system, Platelet, Medical prescription, cost-effectiveness, clopidogrel, Aspirin, business.industry, medicine.disease, Clopidogrel, Cardiovascular Pharmacotherapy, RC666-701, Cardiology, Cardiology and Cardiovascular Medicine, business, Ticagrelor, medicine.drug |
| الوصف: | Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strategies are needed to address this medical need. Aim: To assess the cost-effectiveness of guided DAPT with clopidogrel or ticagrelor in addition to aspirin when using VerifyNow P2Y12 testing in post-ACS patients. Methods: The costs were calculated per 1,000 patients aged >55 years. It was assumed that all patients received either generic clopidogrel or ticagrelor for 1 year, and underwent VerifyNow P2Y12 assay testing before DAPT maintenance. Results: Guided DAPT will prevent five more MIs and six more deaths per 1,000 patients than a standard prescription of generic clopidogrel. The total predictive value of costs per patient is 32% lower if a guided strategy is used than if ticagrelor is given to all patients. Conclusion: Assessment of heightened residual platelet reactivity with P2Y12 assay in triaging DAPT post-ACS patients for 1 year is a cost-effective strategy that would reduce financial burden compared to routine administration of more expensive antiplatelet agents. |
| اللغة: | English |
| تدمد: | 1758-3756 1758-3764 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15b36e84ea8dc7e254ece8d6e4daac7 https://www.ecrjournal.com/articles/Platelet-Function-Guided-Strategy-Clopidogrel-Ticagrelor |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c15b36e84ea8dc7e254ece8d6e4daac7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17583756 17583764 |
|---|